Defining and utilizing surrogates in the evaluation of coronary stents - What do we really want and need to know?

被引：6

作者：

Harrington, Robert A. ^{[1
,2
]}

Hasselblad, Vic ^{[1
]}

Califf, Robert M. ^{[2
,3
]}

机构：

[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA

[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27705 USA

[3] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27705 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2008年 / 51卷 / 01期

关键词：

D O I：

10.1016/j.jacc.2007.08.051

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：33 / 36

页数：4

共 22 条

[11] The enigma of drug-eluting stents - Hope, hype, humility, and advancing patient care [J].

Harrington, Robert A. ;

Ohman, E. Magnus .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :2028-2030

[12] Unanswered questions - Drug-eluting stents and the risk of late thrombosis [J].

Maisel, William H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) :981-984

[13] Risk of cardiovascular events associated with selective COX-2 inhibitors [J].

Mukherjee, D ;

Nissen, SE ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :954-959

[14]

*NIH NAT CTR RES R, CLIN TRANSL SCI AW

[15] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[16] Angiographic surrogate end points in drug-eluting stent trials - A systematic evaluation based on individual patient data from 11 randomized, controlled trials [J].

Pocock, Stuart J. ;

Lansky, Alexandra J. ;

Mehran, Roxana ;

Popma, Jeffrey J. ;

Fahy, Martin P. ;

Na, Yingbo ;

Dangas, George ;

Moses, Jeffirey W. ;

Pucelikova, Tereza ;

Kandzari, David E. ;

Ellis, Stephen G. ;

Leon, Martin B. ;

Stone, Gregg W. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) :23-32

[17] SURROGATE ENDPOINTS IN CLINICAL-TRIALS - DEFINITION AND OPERATIONAL CRITERIA [J].

PRENTICE, RL .

STATISTICS IN MEDICINE, 1989, 8 (04) :431-440

[18] A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors [J].

Schulman, KA ;

Seils, DM ;

Timbie, JW ;

Sugarman, J ;

Dame, LA ;

Weinfurt, KP ;

Mark, DB ;

Califf, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (17) :1335-1341

[19] Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention [J].

Solomon, SD ;

McMurray, JJV ;

Pfeffer, MA ;

Wittes, J ;

Fowler, R ;

Finn, P ;

Anderson, WF ;

Zauber, A ;

Hawk, E ;

Bertagnolli, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1071-1080

[20] Choice of treatment: Outcomes,and treatment goals [J].

Temple, RJ .

AMERICAN HEART JOURNAL, 2003, 146 (04) :565-567

← 1 2 3 →